Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Operating Leases (2022 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Operating Leases for 4 consecutive years, with $37.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Leases rose 13.54% year-over-year to $37.8 million, compared with a TTM value of $37.8 million through Dec 2025, up 13.54%, and an annual FY2025 reading of $37.8 million, up 13.54% over the prior year.
  • Operating Leases was $37.8 million for Q4 2025 at Xeris Biopharma Holdings, down from $38.2 million in the prior quarter.
  • Across five years, Operating Leases topped out at $39.7 million in Q3 2024 and bottomed at $9.4 million in Q4 2022.
  • Average Operating Leases over 4 years is $32.2 million, with a median of $34.9 million recorded in 2023.
  • The sharpest move saw Operating Leases soared 269.75% in 2023, then fell 4.63% in 2025.
  • Year by year, Operating Leases stood at $9.4 million in 2022, then skyrocketed by 269.75% to $34.8 million in 2023, then dropped by 4.33% to $33.3 million in 2024, then rose by 13.54% to $37.8 million in 2025.
  • Business Quant data shows Operating Leases for XERS at $37.8 million in Q4 2025, $38.2 million in Q3 2025, and $32.4 million in Q2 2025.